Cigna does not cover stem cell therapy for joint pain, tendon damage, or arthritis. Under written corporate guidelines, Cigna classifies outpatient regenerative injections as not medically necessary, requiring members to pay the complete bill out of pocket.
Does Cigna Cover Stem Cell Therapy?
Cigna does not cover stem cell therapy for orthopaedic or musculoskeletal conditions, including osteoarthritis of the knee, hip, ankle, and shoulder. Under Cigna Medical Coverage Policy 0552, cellular therapy for joint disease, tendon damage, and tissue repair is classified as not medically necessary. Members seeking outpatient regenerative procedures must plan to fund the treatment entirely on their own.
Coverage exists when specific clinical criteria are satisfied for hospital transplants. Cigna Medical Coverage Policy 0533 covers hematopoietic stem cell transplantation for acute lymphoblastic leukemia and other blood cancers when formal clinical guidelines are met. Cigna also maintains coverage criteria for cellular immunotherapy such as chimeric antigen receptor (CAR) T-cell therapy under Drug Coverage Policy IP0198.
This clear boundary between hospital oncologic care and outpatient joint care matches what occurs across other major commercial carriers. As reviewed in our insurance coverage guide, payers including Blue Cross Blue Shield and Aetna enforce strict non-coverage policies for regenerative injections. Cigna members experience the same payment denials when requesting cellular therapy for musculoskeletal pain.
What Cigna Policy 0552 Says
Cigna Medical Coverage Policy 0552 details the insurer’s position on “Stem Cell Therapy for Orthopaedic Applications.” The policy has an effective date of December 15, 2025, and has a next review date of December 15, 2026.
The document establishes a wide technical definition for cellular therapies used in joint care. Under the scope of Policy 0552:
“For the intent of this Coverage Policy ‘stem cell therapy’ refers to mesenchymal stem cells that are taken from bone marrow, fat tissue, amniotic membrane, and blood and membrane in the joints.”
This definition covers common regenerative clinic procedures, including bone marrow aspirate concentrate and adipose-derived stem cells. Policy 0552 states that stem cell therapy as treatment of orthopaedic or musculoskeletal conditions is considered not medically necessary for:
- Regeneration or repair of musculoskeletal tissue (such as ligament, tendon, or meniscus repair, muscle sprains, tendonitis, and epicondylitis)
- Treatment of joint disease (such as articular cartilage repair and joint capsular injury)
- Osteoarthritis (specifically noting the knee, hip, ankle, and shoulder)
- Fracture repair, including nonunion of long bones
- Osteonecrosis repair
Policy 0552 also itemizes billing codes flagged as not medically necessary. These include Category III Current Procedural Terminology (CPT) codes 0565T and 0566T for adipose-derived cellular implants in knee osteoarthritis, and 0717T and 0718T for adipose-derived cells applied to partial-thickness rotator cuff tears. Standard surgical and harvesting codes 20999, 38230, and 38232 are also restricted under this rule when billed for musculoskeletal repair.
The policy notes that stem cell transplantation for blood cancers, non-cancer disorders, and solid tumors remains out of scope for Policy 0552, which Cigna handles in separate transplant policies. For Medicare Advantage members, the policy notes “No NCD found” and “No LCD found,” meaning Cigna found no Medicare coverage determination for this use.
“Not Medically Necessary” Versus “Experimental”
Many commercial health plans deny regenerative injections using an “experimental and investigational” exclusion. Cigna Policy 0552 uses the specific phrase “not medically necessary” to deny the same procedures. For the patient holding the bill, this difference in terminology changes nothing: both classifications result in a complete denial of benefits.
The policy revision log explains how Cigna arrived at this current phrasing:
- November 1, 2024: A scheduled review removed an earlier policy statement addressing degenerative disc disease. This revision did not make disc injections covered, but rather removed that specific line from the active text. Members considering spinal injections should ask Cigna, citing Policy 0552.
- December 15, 2024: A review revised the stem cell policy statement.
- December 15, 2025: An annual review maintained the clinical policy statements without modifications.
Older third-party summaries still use “experimental” wording. Regardless of whether an automated explanation of benefits cites medical necessity or experimental status, the practical outcome is identical. You remain responsible for the clinic’s charges unless an exception exists within your personal group benefit contract. Under Policy 0552, if a conflict arises, your individual benefit plan document always supersedes the information in corporate coverage policies.
What Cigna Does Cover
Cigna provides coverage for cellular therapies when they are established medical treatments that meet Cigna’s published policy criteria. The differences between covered oncologic care and unapproved joint care appear across multiple published policies.
| Treatment Type | Cigna Policy | Coverage Status | Setting and Billing Terms |
|---|---|---|---|
| Allogeneic hematopoietic transplant (e.g., for ALL) | Policy 0533 | Covered when policy criteria are met | Plan document governs |
| Yescarta CAR-T cell therapy | Policy IP0198 | Covered when policy criteria are met | Any other use not medically necessary; plan document governs |
| Knee osteoarthritis stem cell injection (0565T, 0566T) | Policy 0552 | Not medically necessary | Outpatient clinic; 100 percent patient self-pay |
| Rotator cuff stem cell injection (0717T, 0718T) | Policy 0552 | Not medically necessary | Outpatient clinic; 100 percent patient self-pay |
| Platelet-rich plasma (PRP) injection | Policy 0507 | Experimental, investigational, or unproven | Outpatient clinic; 100 percent patient self-pay |
Policy 0533 states that coverage for hematopoietic stem cell transplantation varies across plans, reminding members to check their benefit documents. The policy confirms that allogeneic transplants are considered medically necessary for conditions like acute lymphoblastic leukemia (ALL) when documented criteria are met. In addition, Cigna maintains separate policies covering transplants for non-cancer conditions and solid tumors. Under Drug Coverage Policy IP0198, Cigna covers Yescarta (axicabtagene ciloleucel) when meeting approved diagnostic thresholds, while declaring Yescarta for any other indication not medically necessary. In contrast, Cigna Policy 0507 excludes platelet-rich plasma, categorizing PRP as experimental, investigational, or unproven for any condition.
The division between covered and non-covered services comes down to the treatment model. Cigna pays for cellular therapy when it is a life-saving transplant performed in a hospital setting to reconstruct a damaged bone marrow system. Cigna does not pay for outpatient injections administered in private orthopaedic offices or regenerative clinics. Understanding the differences between therapy and transplant explains why insurers fund hospital oncologic infusions but reject outpatient joint procedures.
Appealing a Cigna Denial
Members who submit claims for outpatient joint injections receive a formal denial notice on their explanation of benefits. While Cigna provides an established dispute path, filing an appeal for a non-covered orthopaedic injection rarely succeeds.
Under Cigna’s appeals process, disputes start by contacting Customer Service. If informal resolution fails, members can proceed through formal internal appeals. Plans establish specific internal filing windows, so check your plan’s deadline directly on your denial letter. If internal appeals uphold the denial, Cigna notes that members:
“may have the option to submit the dispute for resolution (which is binding upon Cigna Healthcare and the plan) by an independent external reviewer for appeals that involve medical judgment.”
External medical reviewers confirm whether the insurer applied its clinical policies correctly. When a clinic bills an unapproved injection for knee osteoarthritis, the external reviewer compares the claim to Policy 0552. Because the policy explicitly defines musculoskeletal stem cell therapy as not medically necessary, an external reviewer is unlikely to overturn the denial.
Appeals succeed when a covered, approved hospital transplant was rejected due to a clerical mistake, such as an incorrect diagnosis code or missing clinical records. Appeals rarely overturn exclusions for elective joint injections. If an outpatient clinic performs a procedure with the promise that an appeal will force Cigna to pay, you will ultimately be responsible for the unpaid balance.
The Clinical-Trial Route
Some patients consider clinical trials to access cellular medicine under formal medical supervision. In a legitimate research study, coverage rules operate differently than standard clinic fee structures.
When you enroll in an approved trial, the study sponsor typically provides the investigational cellular biologic at no charge to you. Cigna may cover routine patient care costs incurred during the trial, such as standard diagnostic blood work, monitoring imaging scans, and routine physician evaluations that you would require under standard medical care. Cigna does not pay for the experimental cellular product itself.
Legitimate research trials are registered publicly on ClinicalTrials.gov. Legitimate studies do not charge participants thousands of dollars to receive experimental cells. According to the Food and Drug Administration (FDA), patients who are charged high fees for unapproved products outside an authorized clinical trial are likely being deceived.
If a commercial wellness center invites you to join what it calls a private patient registry or internal study for a fee, it is operating a cash-pay medical practice rather than an approved trial. Review our comparison of clinical trials versus cash clinics to examine how commercial registries differ from formal scientific research.
What You Pay Without Coverage
Because Cigna excludes musculoskeletal cellular treatments under Policy 0552, you must cover the full cost out of pocket if you proceed with care. Clinics collect these fees before administering the injection.
Medical Frontier’s published US self-pay ranges include:
- Single joint injection: $3,000 to $8,000 for one knee, hip, or shoulder
- Multiple joints or spinal discs: $6,000 to $15,000 for multi-site care
- Systemic intravenous infusions: $15,000 to $30,000 or more at wellness clinics
- Platelet-rich plasma (PRP): $400 to $2,000 per session, with a full course of two to four treatments running $1,500 to $6,000
If a clinic claims it knows a special billing code to get Cigna to reimburse an orthopaedic stem cell injection, treat that claim as a serious warning sign.
The Bottom Line on Cigna Coverage
Cigna does not pay for stem cell therapy for joint repair, osteoarthritis, or tendon and ligament repair. Cigna Medical Coverage Policy 0552 explicitly classifies cellular injections for orthopaedic applications as not medically necessary. While Cigna covers established hematopoietic stem cell transplants under Policy 0533 and CAR-T therapies under Policy IP0198 for life-threatening blood cancers, these hospital treatments do not apply to joint repair.
This exclusion applies to common autologous bone marrow procedures, adipose tissue harvesting, and birth-tissue products. If your treatment plan does not involve a hospital-based transplant for a diagnosed hematologic disease, you should not choose stem cell therapy expecting reimbursement from Cigna. Our verdict on Cigna coverage would change if the FDA granted formal product approvals for musculoskeletal cellular biologics and Cigna subsequently updated Policy 0552 to establish medical necessity criteria.
Until such regulatory approvals occur, anyone pursuing joint regenerative therapy must budget for complete self-pay expenses. Use our interactive cost estimator to see realistic pricing bands for your joint condition, and consult our overall stem cell cost guide to review self-pay ranges across clinics. If you are comparing coverage across payers, read our guides on Medicare stem cell coverage and how to vet a clinic to avoid unexpected medical bills. Call Cigna Customer Service directly using the number on your member card to verify how your specific benefit plan handles unlisted outpatient injection codes before scheduling any procedure.
Frequently asked questions
Does Cigna cover stem cell therapy?
Cigna covers stem cell therapy only when it involves an established hematopoietic stem cell transplant for specific blood cancers or non-cancer blood disorders. Cigna does not cover stem cell injections for joint damage, osteoarthritis, or tendon repair. Outpatient regenerative injections are classified as not medically necessary under Cigna Medical Coverage Policy 0552.
Does Cigna cover stem cell injections for knees?
No, Cigna does not cover stem cell injections for knee osteoarthritis or cartilage injuries. Policy 0552 explicitly lists knee osteoarthritis as an excluded, not medically necessary indication for cellular therapies. You can review typical self-pay prices in our knee stem cell cost guide.
Does Cigna cover PRP injections?
No, Cigna does not cover platelet-rich plasma (PRP) injections. Under Cigna Medical Coverage Policy 0507, PRP is considered experimental, investigational, or unproven for all clinical conditions. You can read more about commercial coverage rules in our PRP insurance guide.
Does Cigna cover a stem cell transplant?
Yes, Cigna covers hematopoietic stem cell transplants when specific clinical criteria are met for diagnoses such as acute lymphoblastic leukemia under Policy 0533. Coverage varies across plans, so check your benefit plan document.
Can I appeal a Cigna stem cell denial?
You can file an appeal through Cigna Customer Service and request an external review, but appeals rarely reverse denials for outpatient joint injections. Denials for joint injections stem from clear policy exclusions rather than clerical errors. Appeals generally succeed only when an approved hospital transplant procedure was miscoded.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.